Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$29.31 USD

29.31
242,085

+0.02 (0.07%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

Style Box ETF report for IJT

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

Style Box ETF report for SLYG

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?

MDRX vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?

Style Box ETF report for SLY

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Add Patterson Companies (PDCO) to Your Portfolio

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes

Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.

BD's (BDX) New Combination Test to Boost Patient Outcome

BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.

Catalent (CTLT) Expands Packaging Capabilities at Japan Facility

Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.

Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes

Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.

Cardinal Health (CAH) Ties Up to Deliver Products Via Drones

Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.

3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?

Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.

Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis

Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.

ENOV vs. OMCL: Which Stock Should Value Investors Buy Now?

ENOV vs. OMCL: Which Stock Is the Better Value Option?

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

Style Box ETF report for SLYG

3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care

Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.

Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

McKesson's (MCK) Latest JV to Boost Cancer Treatment Options

McKesson's (MCK) latest activities in the oncology care space is expected to serve a wider patient pool.